發(fā)布時間：2018-09-11 11:45

【摘要】：目的:本研究通過研究呼出氣一氧化氮和肺功能在慢性阻塞性肺疾病與慢性阻塞性肺疾病合并支氣管哮喘綜合征(ACOS)之間的差異,初步探討呼出氣一氧化氮和肺功能在慢阻肺患者中篩選慢阻肺-哮喘重疊綜合征的臨床意義。方法:本研究采用病例-對照研究,收集2016年1月至2017年1月在新疆醫(yī)科大學(xué)第五附屬醫(yī)院就診的ACOS急性發(fā)作患者50例、慢阻肺急性發(fā)作患者50例。所有患者簽署研究知情同意書。(1)臨床資料收集:研究對象的年齡、性別、吸煙指數(shù)、血沉、血常規(guī)、血清總IgE、胸部X片。⑵研究內(nèi)容:測定入選者肺功能指標(biāo),包括第一秒用力呼氣容積(FEV1),用力肺活量(FVC)及兩者的比值(FEV1/FVC),第一秒用力呼氣容積占預(yù)計值百分比(FEV1%red)。(3)按美國胸科協(xié)會推薦的成人及兒童呼出氣一氧化氮(FENO)水平測量技術(shù)的標(biāo)準(zhǔn),我們采用Niox化學(xué)發(fā)光分析儀(Aerocrine,Solna,Sweden)檢測FENO。重復(fù)測量3次,3次的測量結(jié)果要達(dá)到基本一致。結(jié)果:(1)ACOS組和慢阻肺組平均年齡分別為(72.2±11.8)歲和(71.2±10.8)歲,無顯著差異(P0.05)。(2)ACOS組和慢阻肺組吸煙指數(shù)分別為(472±127)年支和(482±91)年支(P0.05)。(3)兩組之間經(jīng)卡方檢驗比較性別,P0.05,組間差異無統(tǒng)計學(xué)意義:(4)ACOS組FENO計數(shù)高于單純COPD組(P0.05)。(5)ACOS組和慢阻肺組FENO分別為(55.2±27.3)ppb和(19.1±10.1)ppb(P0.05)。(6)以45ppb為切點,FENO的增高率,ACOS組(88.0%)顯著高于慢阻肺組(10.0%)(P0.01)。(7)FVC、FEV1/FVC、FEV1%red在慢阻肺與ACOS之間無顯著差異。結(jié)論:1.本研究FENO數(shù)值在ACOS組高于COPD組,當(dāng)以45ppb為節(jié)點時ACOS組的增高率遠(yuǎn)遠(yuǎn)大于COPD組,提示了FENO在慢阻肺患者中初篩選哮喘-慢阻肺重疊綜合征的具有一定應(yīng)用價值。2.肺功能(FVC、FEV1/FVC、FEV1%red)在ACOS組與COPD組無明顯差別,用于慢阻肺患者中初篩選哮喘-慢阻肺重疊綜合征的價值不大。
[Abstract]:Objective: to study the difference of exhaled nitric oxide (no) and pulmonary function in (ACOS) between chronic obstructive pulmonary disease (COPD) and chronic obstructive pulmonary disease (COPD) with bronchial asthma syndrome. To explore the clinical significance of respiratory nitric oxide (no) and pulmonary function in screening COPD-asthma overlap syndrome. Methods: from January 2016 to January 2017, 50 patients with acute attack of ACOS and 50 patients with acute attack of chronic obstructive pulmonary disease (COPD) from January 2016 to January 2017 in the Fifth affiliated Hospital of Xinjiang Medical University were enrolled in this study. (1) Clinical data collection: age, sex, smoking index, erythrocyte sedimentation rate, blood routine examination, total serum IgE, chest X-ray. 2. It included forced expiratory volume (FEV1), forced vital capacity (FVC) and their ratio (FEV1/FVC), and forced expiratory volume in the first second (FEV1%red). (3) according to the standard of exhale nitric oxide (FENO) level in adults and children recommended by the American Thoracic Association. We use Niox chemiluminescence analyzer (Aerocrine,Solna,Sweden) to detect FENO.. The results of repeated measurements 3 times and 3 times should be basically consistent. Results: (1) the average age of ACOS group and COPD group were (72.2 鹵11.8) years and (71.2 鹵10.8) years, respectively. There was no significant difference (P0.05). (2) between the two groups (P0.05). (2). The smoking index of ACOS group and chronic obstructive lung group were (472 鹵127) years and (482 鹵91) year branches respectively (P0.05). (3). There was no significant difference between the two groups by chi-square test (P 0.05). (4) the FENO count of ACOS group was higher than that of COPD group (P0.05). (5) ACOS group and chronic obstructive lung group (P 0.05). The increase rate of FENO in 45ppb group (88.0%) was significantly higher than that in chronic obstructive lung group (10.0%) (P0.01). (7). There was no significant difference between 45ppb and ACOS. Conclusion 1. The FENO value of this study was higher in ACOS group than in COPD group, and the increase rate in ACOS group was much higher than that in COPD group when 45ppb was used as the node. It suggested that FENO was valuable in screening the asthmatic / chronic obstructive lung overlap syndrome in COPD patients. Pulmonary function (FVC,FEV1/FVC,FEV1%red) had no significant difference between ACOS group and COPD group.
【學(xué)位授予單位】：新疆醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R563.9;R562.25

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 各廷秋;張念志;王陶;張潤;黃鶴;田靜;;呼出氣一氧化氮(FeNO)檢測在慢性阻塞性肺疾病中的應(yīng)用進(jìn)展[J];臨床肺科雜志;2017年01期

2 劉冬;許西琳;辛雯艷;蔣雪龍;魯?shù)聅，

本文編號：2236601